A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma

References

• Sung H , FerlayJ, SiegelRLet al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Sjoquist KM , BurmeisterBH, SmithersBMet al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol.12(7), 681–692 (2011).
   PubMed Web of Science ®Google Scholar
• Ajani JA , D’amicoTA, BentremDJet al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Cancer Netw.17(7), 855–883 (2019).
   PubMed Web of Science ®Google Scholar
• Kitagawa Y , UnoT, OyamaTet al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus16(1), 1–24 (2019).
   PubMed Web of Science ®Google Scholar
• Van Hagen P , HulshofMC, Van LanschotJJet al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med.366(22), 2074–2084 (2012).
   PubMed Web of Science ®Google Scholar
• Ando N , KatoH, IgakiHet al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann. Surg. Oncol.19(1), 68–74 (2012).
   PubMed Web of Science ®Google Scholar
• Blum Murphy M , XiaoL, PatelVRet al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival – The University of Texas MD Anderson Cancer Center experience. Cancer123(21), 4106–4113 (2017).
   PubMed Web of Science ®Google Scholar
• Samson P , PuriV, LockhartACet al. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival. J. Thorac. Cardiovasc. Surg.156(4), 1725–1735 (2018).
   PubMed Web of Science ®Google Scholar
• Semenkovich TR , SubramanianM, YanYet al. Adjuvant therapy for node-positive esophageal cancer after induction and surgery: a multisite study. Ann. Thorac. Surg.108(3), 828–836 (2019).
   PubMed Web of Science ®Google Scholar
• Kelly RJ , AjaniJA, KuzdzalJet al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med.384(13), 1191–1203 (2021).
   PubMed Web of Science ®Google Scholar
• Lordick F , MarietteC, HaustermansK, ObermannovaR, ArnoldD, CommitteeEG. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27(Suppl. 5), v50–v57 (2016).
   PubMed Web of Science ®Google Scholar
• Shin S , KimHK, ChoiYS, KimK, ShimYM. Clinical stage T1–T2N0M0 oesophageal cancer: accuracy of clinical staging and predictive factors for lymph node metastasis. Eur. J. Cardiothorac. Surg.46(2), 274–279; discussion 279 (2014).
   PubMed Web of Science ®Google Scholar
• Crabtree TD , YacoubWN, PuriVet al. Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival. Ann. Thorac. Surg.91(5), 1509–1515; discussion 1515–1506 (2011).
   PubMed Web of Science ®Google Scholar
• Crabtree TD , KosinskiAS, PuriVet al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann. Thorac. Surg.96(2), 382–390 (2013).
   PubMed Web of Science ®Google Scholar
• Haque W , VermaV, BernickerE, ButlerEB, TehBS. Management of pathologic node-positive disease following initial surgery for clinical T1–2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base. Acta Oncol.57(6), 782–789 (2018).
   PubMed Web of Science ®Google Scholar
• Feng SK , LiuXB, XingWQet al. Adjuvant chemotherapy for node-positive esophageal squamous cell carcinoma improves survival. Ann. Thorac. Surg.114(4), 1205–1213 (2022).
   PubMed Web of Science ®Google Scholar
• Gao SJ , ParkHS, CorsoCD, RutterCE, KimAW, JohungKL. Role of adjuvant treatment in esophageal cancer with incidental pathologic node positivity. Ann. Thorac. Surg.104(1), 267–274 (2017).
   PubMed Web of Science ®Google Scholar
• Rice TW , IshwaranH, FergusonMK, BlackstoneEH, GoldstrawP. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J. Thorac. Oncol.12(1), 36–42 (2017).
   PubMed Web of Science ®Google Scholar
• Sun HB , XingWQ, LiuXBet al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer20(1), 303 (2020).
   PubMed Web of Science ®Google Scholar
• World Medical Association I . Declaration of Helsinki. Ethical principles for medical research involving human subjects. J. Indian Med. Assoc.107(6), 403–405 (2009).
   PubMedGoogle Scholar
• Obermannova R , AlsinaM, CervantesAet al. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol.33(10), 992–1004 (2022).
   PubMed Web of Science ®Google Scholar
• Shah MA , KennedyEB, CatenacciDVet al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J. Clin. Oncol.38(23), 2677–2694 (2020).
   PubMed Web of Science ®Google Scholar
• Toh Y , YamamotoH, MiyataHet al. Significance of the board-certified surgeon systems and clinical practice guideline adherence to surgical treatment of esophageal cancer in Japan: a questionnaire survey of departments registered in the National Clinical Database. Esophagus.16(4), 362–370 (2019).
   PubMed Web of Science ®Google Scholar
• Weber J , MandalaM, DelVecchio Met al. Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med.377(19), 1824–1835 (2017).
   PubMed Web of Science ®Google Scholar
• Speicher PJ , GanapathiAM, EnglumBRet al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. J. Thorac. Oncol.9(8), 1195–1201 (2014).
   PubMed Web of Science ®Google Scholar
• Stiles BM , MirzaF, CoppolinoAet al. Clinical T2–T3N0M0 esophageal cancer: the risk of node positive disease. Ann. Thorac. Surg.92(2), 491–496; discussion 496–498 (2011).
   PubMed Web of Science ®Google Scholar
• Wang J , FeiK, JingHet al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs11(8), 1443–1451 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang L , MaiW, JiangW, GengQ. Sintilimab: a promising anti-tumor PD-1 antibody. Front. Oncol.10, 594558 (2020).
   PubMed Web of Science ®Google Scholar
• Lu Z , WangJ, ShuYet al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ377, e068714 (2022).
   PubMedGoogle Scholar
• Kojima T , ShahMA, MuroKet al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol.38(35), 4138–4148 (2020).
   PubMed Web of Science ®Google Scholar
• Doki Y , AjaniJA, KatoKet al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med.386(5), 449–462 (2022).
   PubMed Web of Science ®Google Scholar
• Luo H , LuJ, BaiYet al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA326(10), 916–925 (2021).
   PubMed Web of Science ®Google Scholar
• Doi T , Piha-PaulSA, JalalSIet al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J. Clin. Oncol.36(1), 61–67 (2018).
   PubMed Web of Science ®Google Scholar
• Patel MA , KratzJD, LubnerSJ, LoconteNK, UbohaNV. Esophagogastric cancers: integrating immunotherapy therapy into current practice. J. Clin. Oncol.40(24), 2751–2762 (2022).
   PubMed Web of Science ®Google Scholar